New agents such as BTK and BCL2 inhibitors have changed the treatment paradigms of high-risk and/or elderly patients with CLL [1,2], but the long-term efficacies and toxicities are still unknown and the costs are considerable. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.